We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is AllScripts Healthcare (MDRX) Outperforming Other Medical Stocks This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. AllScripts Healthcare (MDRX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AllScripts Healthcare is one of 1160 companies in the Medical group. The Medical group currently sits at #8 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AllScripts Healthcare is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for MDRX's full-year earnings has moved 8.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, MDRX has returned 9.9% so far this year. In comparison, Medical companies have returned an average of -17.2%. This shows that AllScripts Healthcare is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Pharvaris N.V. (PHVS - Free Report) . The stock has returned 18.1% year-to-date.
For Pharvaris N.V. the consensus EPS estimate for the current year has increased 12.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, AllScripts Healthcare is a member of the Medical Info Systems industry, which includes 47 individual companies and currently sits at #99 in the Zacks Industry Rank. This group has lost an average of 50.3% so far this year, so MDRX is performing better in this area.
On the other hand, Pharvaris N.V. belongs to the Medical - Biomedical and Genetics industry. This 538-stock industry is currently ranked #158. The industry has moved -33.9% year to date.
AllScripts Healthcare and Pharvaris N.V. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is AllScripts Healthcare (MDRX) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. AllScripts Healthcare (MDRX - Free Report) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question.
AllScripts Healthcare is one of 1160 companies in the Medical group. The Medical group currently sits at #8 within the Zacks Sector Rank. The Zacks Sector Rank gauges the strength of our 16 individual sector groups by measuring the average Zacks Rank of the individual stocks within the groups.
The Zacks Rank is a proven model that highlights a variety of stocks with the right characteristics to outperform the market over the next one to three months. The system emphasizes earnings estimate revisions and favors companies with improving earnings outlooks. AllScripts Healthcare is currently sporting a Zacks Rank of #2 (Buy).
Over the past 90 days, the Zacks Consensus Estimate for MDRX's full-year earnings has moved 8.3% higher. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive.
Based on the most recent data, MDRX has returned 9.9% so far this year. In comparison, Medical companies have returned an average of -17.2%. This shows that AllScripts Healthcare is outperforming its peers so far this year.
Another Medical stock, which has outperformed the sector so far this year, is Pharvaris N.V. (PHVS - Free Report) . The stock has returned 18.1% year-to-date.
For Pharvaris N.V. the consensus EPS estimate for the current year has increased 12.3% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Breaking things down more, AllScripts Healthcare is a member of the Medical Info Systems industry, which includes 47 individual companies and currently sits at #99 in the Zacks Industry Rank. This group has lost an average of 50.3% so far this year, so MDRX is performing better in this area.
On the other hand, Pharvaris N.V. belongs to the Medical - Biomedical and Genetics industry. This 538-stock industry is currently ranked #158. The industry has moved -33.9% year to date.
AllScripts Healthcare and Pharvaris N.V. could continue their solid performance, so investors interested in Medical stocks should continue to pay close attention to these stocks.